Thyrotropin Alfa clinical trials
How each study uses Thyrotropin Alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Thyrotropin Alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 30 Nov 1998 · THYROGEN · BLA 020898 (FDA, Drugs@FDA)
- European Union
- 9 Mar 2000 · Thyrogen · EMEA/H/C/000220 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2006 (3)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2012 | 1 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 8
Suzhou Zelgen Biopharmaceuticals Co.,Ltd (4) · Genzyme, a Sanofi Company (2) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2) · University College, London (1) · Genexine, Inc. (1) · University of Colorado, Denver (1) · Steen Bonnema (1) · Copenhagen University Hospital at Herlev (1)
Often tested with
Tested in the same studies.
Iodide ion i-131 (1) · Pre-Procedure Thyroid Hormone Therapy Withdrawal (1) · IODE 131 (1)
Studies
Open first, then newest update. How each study uses Thyrotropin Alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid CancerRecruitingPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT03841617Written as Thyrogen
- rhTSH for Radioactive Iodine Remnant Ablation in Participants With Differentiated Thyroid Cancer (DTC)CompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04964284Written as rhTSH
- rhTSH for Radioactive Iodine Remnant Ablation in Differentiated Thyroid CancerCompletedPhase 2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04447183Written as Recombinant Human Thyroid Stimulating Hormone for Injection(rhTSH)
- Comparison of the Efficacy and Safety of rhTSH as An Adjunctive Diagnostic Tool in Differentiated Thyroid Cancer Patients Who Had Been Thyroidectomized Vs. Patients Who After Thyroid Hormone WithdrawalCompletedPhase 3Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04971473Written as rhTSH
- Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized PatientsCompletedPhase 1/2Suzhou Zelgen Biopharmaceuticals Co.,LtdNCT04137185Written as Recombinant Human Thyroid Stimulating Hormone for Injection
- High Dose vs Low Dose I 131 +/- rhTSH for Differentiated Thyroid CancerActive, not recruitingPhase 3University College, LondonNCT00415233Written as recombinant thyroid-stimulating hormone
- Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy PatientsCompletedPhase 1/2Genexine, Inc.NCT03276988Written as Period 1 GX-30, Period 2 THYROGEN®
- Evaluation of Thyroid Stunning From a Diagnostic Dose of I-123CompletedPhase 1University of Colorado, DenverNCT02278198Written as rhTSH
- Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (no Thyrogen) Following 131I AdministrationCompletedPhase 3Genzyme, a Sanofi CompanyNCT00196729Written as Thyrogen + Radioiodine (131I)
- A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.CompletedPhase 3Genzyme, a Sanofi CompanyNCT00295763Written as Thyrogen (thyrotropin alfa for injection)
- rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular GoiterCompletedPhase 2Steen BonnemaNCT00275171Written as Recombinant human thyrotropin (Thyrogen)
- Quality of Life, Recombinant TSH (Thyrogen) and Thyroid CancerCompletedPhase 4Copenhagen University Hospital at HerlevNCT00604318Written as rhTSH
- rhTSH, Thyroid Size, and Radioiodine Therapy in Benign GoiterCompletedPhase 2Odense University HospitalNCT00145366Written as Recombinant human thyrotropin (Thyrogen)
- Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.CompletedPhase 4National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00001730Written as Thyrogen
- Medico-Economic Comparison of Four Strategies of Radioiodine Ablation in Thyroid Carcinoma PatientsStatus unknownPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT00435851Written as Thyrogen, thyroid hormone withdrawal, iode 131
Given beside what is tested · 6 — Thyrotropin Alfa is usual care or a partner of the new treatment
- Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingPhase 2City of Hope Medical CenterNCT06440850Written as Recombinant Thyrotropin Alfa
- Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TCTerminatedPhase 2Massachusetts General HospitalNCT05668962Written as rhTSH
- Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid CancerCompletedPhase 2Gustave Roussy, Cancer Campus, Grand ParisNCT03244956Written as rhTSH
- Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot StudyCompletedEarly Phase 1Memorial Sloan Kettering Cancer CenterNCT02145143Written as thyrotropin alpha
- Differentiated Thyroid Cancer: is There a Need for Radioiodine Ablation in Low Risk Patients?Active, not recruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT01837745Written as rhTSH stimulation
- Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131CompletedPhase 2National Cancer Institute (NCI)NCT00085293Written as Recombinant thyrotropin alfa
Codes
What other systems call Thyrotropin Alfa · ClinicalTrials.gg INT008918
- MeSH (NLM) D057073Thyrotropin AlfaConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) AVX3D5A4LMTHYROTROPIN ALFAConfirmed FDA, Wikidata
- RxNorm 4952Confirmed FDA, Wikidata
- Wikidata Q20816877thyrotropin alfaConfirmed FDA, Wikidata
- NCI Thesaurus C61322Recombinant Thyrotropin AlfaOne source FDA
- DrugBank DB00024One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D057073 | Thyrotropin Alfa | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | AVX3D5A4LM | THYROTROPIN ALFA | Confirmed FDA, Wikidata |
| RxNorm | 4952 | — | Confirmed FDA, Wikidata |
| Wikidata | Q20816877 | thyrotropin alfa | Confirmed FDA, Wikidata |
| NCI Thesaurus | C61322 | Recombinant Thyrotropin Alfa | One source FDA |
| DrugBank | DB00024 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.